Navigation Links
KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results
Date:8/11/2008

M) will make a significant contribution to Ther-Rx revenues during the second half of fiscal 2009.

ETHEX Corporation -- 53% Net Sales Growth Due to Metoprolol Succinate

ETHEX Corporation net sales of $92.3 million in the first quarter represented a 52.6% increase compared to the prior year first quarter of $60.5 million. Sales growth during the quarter was impacted by volume growth from the sale of all four strengths of metoprolol succinate extended-release tablets, which contributed $35.5 million in net revenues during the quarter, offset in part by the reduced level of sales from our discontinued cough/cold product line.

ETHEX's cough/cold product line, except for one product, was discontinued earlier this calendar year following a shift in FDA policy on products containing guaifenesin. Our currently marketed generic cough/cold product generated net revenues of $0.5 million during the quarter, compared with sales of the entire cough/cold product line of $9.3 million for the first quarter of fiscal 2008.

ETHEX's profitability remained strong for another quarter as measured by its gross profit margins of 60.5%, compared to gross margins of 56.0% in the first quarter of fiscal 2008.

The ETHEX pipeline remains strong. Last year we filed 16 ANDA's and this year we expect to file another 16 ANDA's. During this fiscal year, we expect six ANDA approvals, following five ANDA approvals received by KV in our preceding fiscal year. In addition, ETHEX believes it is the first to file for a number of Paragraph IV generic products with significant revenue contribution potential.

Outlook for the Year

The Company currently expects to report net revenue of between $650 million and $675 million and net income per diluted Class A share of between $1.65 and $1.75 for the fiscal year ending March 31, 2009. Although KV historically has not issued revenue or earnings guidance, in light of potential competitive challenges related to certain
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 02, 2015 Colleen’s Dream Foundation ... granted $70,000 to the UNMC to support ovarian cancer research ... Cundiff, a member of the Colleen’s Dream Foundation Board of ... the biggest to date for Colleen’s Dream Foundation and they ... Omaha. , “Dr. Wang is a rising star in the ...
(Date:6/2/2015)... June 02, 2015 While the movie ... of comic books, comic books themselves are stepping into ... Uniting Nations plans to produce educational comics in multiple ... Goals for Sustainable Development - an international effort to ... hunger, health, education, sustainable energy, inequality, climate change and ...
(Date:6/2/2015)... 02, 2015 Pacifica Graduate Institute ... up by current and former students to honor the ... member from 2002 until his death in 2013. His ... depth of feeling, as well as his passion for ... as an analyst, teacher, and writer were felt in ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Lynn Lester as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... Lester with this prestigious award,” said NAPW President Star ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Linda Cade as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” said NAPW President Star Jones. ...
Breaking Medicine News(10 mins):Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 2Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 3Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2
... RIDGE, N.J., Oct. 19 VioQuest,Pharmaceuticals (OTC ... focused on acquiring, developing and,commercializing targeted cancer ... data in poster presentations pertaining to VQD-002 ... and Cancer Therapeutics",International Conference sponsored by the ...
... CSV ) today announced plans to release 2007 third quarter ... conjunction with the,release, Carriage Services has scheduled a conference call, ... 2, 2007 at 10:00,a.m. eastern time. What: ... When: Friday, November 2, 2007 ...
... Amedisys, Inc.,(Nasdaq: AMED or the "Company"), one of ... intends to release its financial,results for the quarter ended ... Company will also host a conference call with the,investment ... To participate in the conference call, please dial 800-683-1525,(Domestic) ...
... US Oncology Holdings, Inc. and its,operating subsidiary, US ... on Thursday, November 8, 2007. A conference ... at 10:00,a.m., EST, for the company,s bondholders following ... representatives of US Oncology,s management,team will discuss the ...
... poor, uninsured,women in Pennsylvania will no longer have ... Prevention Project has ended. "Poor,women are going to ... funding for this critical program," declared Dorothy Mann, ... "We had a,Democratic supporter who worked with a ...
... Association of,Dental Plans (NADP) calls on Congress and the ... Program (CHIP).,Specifically, NADP urges prompt action to enact the ... bill., In letters to congressional health policy leaders, ... Dental services should be a mandatory CHIP benefit. ...
Cached Medicine News:Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 2Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 3Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 4Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 5Health News:Carriage Services Announces Third Quarter Earnings Release and Conference Call Schedule 2Health News:Amedisys to Host Conference Call to Discuss Third Quarter Financial Performance and Operating Results 2Health News:Pa. Funding for Cervical Cancer Prevention Services Ends 2Health News:NADP Calls on Congress and the White House to Work Together to Cover Children's Dental Health 2
(Date:6/1/2015)... PARK, Calif. , June 1, 2015 ... device company that is providing innovative evidence-based solutions for ... has commenced an underwritten public offering of its common ... Nevro and 2,459,175 shares to be sold by certain ... the underwriters a 30-day option to purchase up to ...
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, today announced ... trial of  VAL-083  (dianhydrogalactitol) in patients with refractory ... form of human brain cancer. Results ...
(Date:6/1/2015)... CEFALY Technology , the creators of ... authorized for use prior to the onset of migraine ... trial showing that the Cefaly device returns normal metabolic ... patients, namely the orbitofrontal cortex and rostral cingulate. ... an imaging test of the brain, used a radioactive substance called a ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... Lobob hard contact lens cleaning ... to use, and professionally proven ... non-ionic detergents resulting in a ... protein deposits, cosmetic residue, salts, ...
Optimum C/D/S Solution is a sterile cleaning, disinfecting, and storage solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and hard contact lenses....
Round knurled handle. Overall length 130 mm....
5 inch (12.7 cm), 2 x 5 mm blade....
Medicine Products: